Search research articles
Contact Us
Filters
Showing results (291-300 of 299) with videos related to
Page
of 30
Sort By:
You have reached the last page of results.
This site can display upto 299 results.
Frontiers in Neurology
|
February 6, 2019
Enduring Neuroprotective Effect of Subacute Neural Stem Cell Transplantation After Penetrating TBI
Anelia A Y Kassi, Anil K Mahavadi, Angelica Clavijo, et al.
Lancet (London, England)
|
September 2, 2017
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, et al.
Annals of the Rheumatic Diseases
|
May 1, 2026
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis
Hermine I Brunner, Mittermayer Santiago, Beth Gottlieb, et al.
Circulation
|
December 28, 2018
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, et al.
Journal of the American College of Cardiology
|
April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?
Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
Cardiovascular Drugs and Therapy
|
July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference
Thomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Lancet (London, England)
|
August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
John G F Cleland, John R Teerlink, Roxy Senior, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 2, 2017
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
Ian Graham, Chuck Shear, Pieter De Graeff, et al.
European Journal of Heart Failure
|
June 22, 2013
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
Faiez Zannad, Angeles Alonso Garcia, Stefan D Anker, et al.
Page
of 30
Search research articles
Search
Showing results (291-300 of 299) with videos related to
Sort By:
Page
of 30
You have reached the last page of results.
This site can display upto 299 results.
Frontiers in Neurology
|
February 6, 2019
Enduring Neuroprotective Effect of Subacute Neural Stem Cell Transplantation After Penetrating TBI
Anelia A Y Kassi, Anil K Mahavadi, Angelica Clavijo, et al.
Lancet (London, England)
|
September 2, 2017
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P Giugliano, Terje R Pedersen, Jeong-Gun Park, et al.
Annals of the Rheumatic Diseases
|
May 1, 2026
Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis
Hermine I Brunner, Mittermayer Santiago, Beth Gottlieb, et al.
Circulation
|
December 28, 2018
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk
Michelle L O'Donoghue, Sergio Fazio, Robert P Giugliano, et al.
Journal of the American College of Cardiology
|
April 18, 2015
Cardiovascular drug development: is it dead or just hibernating?
Christopher B Fordyce, Matthew T Roe, Tariq Ahmad, et al.
Cardiovascular Drugs and Therapy
|
July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference
Thomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Lancet (London, England)
|
August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
John G F Cleland, John R Teerlink, Roxy Senior, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
December 2, 2017
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
Ian Graham, Chuck Shear, Pieter De Graeff, et al.
European Journal of Heart Failure
|
June 22, 2013
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document
Faiez Zannad, Angeles Alonso Garcia, Stefan D Anker, et al.
Page
of 30